POLE and colorectal carcinoma: Also, using Memorial Sloan Kettering Cancer Center (MSK)-IMPACT, a capture-based NGS platform that can detect mutations and copy-number alterations, and select rearrangements in 341 or more cancer genes, MSK cohort provided a resource for further studies of the biology of CRC.21 Similar to other tumors, in addition to the well-established driver genes, low-frequency mutations or other oncogenic events were also discovered by NGS test.20 21 The DNA polymerase genes ɛ (POLE) and δ (POLD1) were two potential biomarkers in CRC of low mutation frequencies.